Lilly Announced Nearly 80% Of Patients With Moderate-to-severe Atopic Dermatitis Maintained Clear Or Almost Clear Skin With Lebrikizumab Monthly Maintenance Dosing At Two Years

Press/Media

Period20 Oct 2023

Media coverage

1

Media coverage

  • TitleLilly Announced Nearly 80% Of Patients With Moderate-to-severe Atopic Dermatitis Maintained Clear Or Almost Clear Skin With Lebrikizumab Monthly Maintenance Dosing At Two Years
    Media name/outletBENZINGA Newswire
    Country/TerritoryUnited States
    Date20/10/23
    PersonsEmma Guttman